Feline Chronic Bronchitis (Non-Allergic)

Feline chronic bronchitis (non-allergic) is a lower airway disease of cats characterized by persistent inflammation of the bronchi and bronchioles that is not driven by an identifiable allergic (atopic) mechanism. Unlike feline asthma, which is classically associated with eosinophilic airway inflammation and hypersensitivity responses, non-allergic chronic bronchitis is defined by a sustained neutrophilic or mixed inflammatory infiltrate leading to irreversible or partially reversible structural airway changes. The condition is clinically significant because the chronic inflammation can progress to airway remodeling, bronchiectasis, and permanent functional impairment. It is distinct from infectious bronchitis and is not transmissible between cats.

The etiology of non-allergic feline chronic bronchitis is multifactorial and in many cases remains incompletely defined, hence the use of the term "idiopathic" in some references. Several contributing factors have been identified:

Irritant Exposure: Chronic inhalation of environmental irritants — including cigarette smoke, dusty cat litter, aerosol cleaning products, perfumes, and indoor air pollutants — is a well-recognized inciting factor. Repeated low-level irritant exposure triggers innate immune responses in the airway epithelium without activating the IgE-mediated pathways characteristic of true allergic disease.

Infectious Antecedents: Prior respiratory infections (e.g., Mycoplasma felis, Bordetella bronchiseptica, or viral upper respiratory agents) may cause ongoing or smoldering airway inflammation that transitions into a chronic non-resolving state even after the primary pathogen is eliminated. Mycoplasma in particular has been associated with neutrophilic airway inflammation in cats.

Pathological Mechanism: The dominant inflammatory cell in non-allergic chronic bronchitis is the neutrophil, rather than the eosinophil seen in asthma. Neutrophil-derived proteases (e.g., elastase, matrix metalloproteinases) degrade extracellular matrix components, disrupting mucociliary clearance and causing goblet cell hyperplasia. The resulting excess mucus production further narrows the airway lumen. Chronic stimulation of fibroblasts leads to subepithelial fibrosis and smooth muscle hypertrophy, contributing to irreversible airway remodeling. Unlike asthma, bronchospasm is a less prominent feature; the obstruction is more fixed and structural. Progressive remodeling can culminate in bronchiectasis — permanent dilation and distortion of bronchi — which further impairs secretion clearance and predisposes to recurrent secondary infections, creating a self-perpetuating cycle of inflammation and damage.

Breed and Age Predisposition: Middle-aged to older cats appear most commonly affected. No strong breed predilection has been consistently established, though some clinicians observe higher representation in domestic shorthairs reflecting population demographics.

Diagnosis of feline chronic bronchitis (non-allergic) is reached by a combination of clinical history, physical examination, diagnostic imaging, airway sampling, and exclusion of other causes of chronic cough.

Clinical History and Physical Examination: A history of cough lasting ≥8 weeks in a cat with no prior diagnosis of asthma or infectious disease is a key criterion. Auscultation typically reveals diffuse expiratory crackles or wheezes; increased bronchovesicular sounds are common. Fever is typically absent unless secondary infection is present.

Thoracic Radiography: Chest radiographs are essential and frequently show a prominent bronchial pattern ("doughnuts and tramlines" — thickened bronchial walls seen in cross-section and longitudinal section, respectively). Air trapping and hyperinflation may be present but tend to be less dramatic than in classic asthma. Bronchiectasis (bronchial dilation) may be visible in advanced cases and is an important negative prognostic indicator. Radiographs also help exclude concurrent pneumonia, pleural effusion, neoplasia, and cardiac disease.

Bronchoscopy: Flexible bronchoscopy allows direct visualization of the airway mucosa, revealing hyperemia, mucosal irregularity, excess secretions, and loss of normal bronchial architecture. Bronchiectasis may be directly observed. Bronchoscopy is also invaluable for targeted sampling.

Bronchoalveolar Lavage (BAL) and Transtracheal Wash (TTW): BAL cytology is the gold standard for characterizing the inflammatory cell population. In non-allergic chronic bronchitis, the predominant cells are neutrophils (typically >15% of the total differential count, often much higher); eosinophil counts are low or normal (<17%), which distinguishes this condition from feline asthma. BAL samples should always be submitted for aerobic/anaerobic bacterial culture and Mycoplasma PCR to exclude ongoing infection. Cytology may also reveal degenerate neutrophils and intracellular bacteria if secondary infection is present.

Laboratory Testing:

• ·CBC: The complete blood count may show a mild leukocytosis with a neutrophilia in active disease or during exacerbations. Eosinophilia would suggest an allergic/parasitic process rather than non-allergic bronchitis.
  • ·WBC: May be mildly elevated (reference: 5.5–19.5 × 10³/µL); neutrophilia without a left shift is typical of chronic disease.
  • ·HCT/PCV: Usually within normal limits; mild polycythemia could develop in cases with chronic hypoxemia.
  • ·PLT: Typically normal unless concurrent systemic illness is present.
• ·Serum Chemistry Panel:
  • ·ALT: Generally normal unless hepatic involvement from hypoxia or concurrent disease is present.
  • ·GLOB: May be mildly elevated reflecting chronic antigenic stimulation.
  • ·BUN/CREA: Usually normal; important for baseline before initiating therapies (especially NSAIDs or long-term corticosteroids which can affect renal function).
  • ·ALB: Typically normal; hypoalbuminemia would suggest protein-losing disease or malnutrition from severe chronic illness.
  • ·TBIL: Usually normal.
• ·Heartworm Antigen/Antibody Test: Mandatory in endemic regions, as feline heartworm disease can produce a radiographic and clinical picture nearly identical to chronic bronchitis/asthma.
• ·Fecal Flotation and Baermann Technique: To rule out lungworm (e.g., Aelurostrongylus abstrusus), a common mimic.
• ·Feline Respiratory Pathogen PCR Panel: From BAL or nasal swab to screen for Mycoplasma felis, Bordetella bronchiseptica, feline herpesvirus-1, feline calicivirus, and Chlamydophila felis.

Computed Tomography (CT): High-resolution CT of the thorax is more sensitive than radiography for detecting early bronchiectasis, mucus plugging, and the extent of airway remodeling, and is increasingly available at referral centers.

Pulmonary Function Testing: Barometric whole-body plethysmography (BWBP) can detect increased airway resistance and is used in research and some referral settings to objectively assess airflow obstruction and monitor treatment response.

Diagnostic Criteria: Definitive diagnosis requires: (1) chronic cough ≥8 weeks, (2) radiographic bronchial pattern, (3) neutrophilic airway inflammation on BAL cytology, and (4) exclusion of infectious, parasitic, neoplastic, and cardiac causes.

Treatment of feline chronic bronchitis (non-allergic) is aimed at reducing airway inflammation, improving mucociliary clearance, managing exacerbations, and slowing structural progression. Because the condition is often idiopathic and associated with irreversible changes, management is typically long-term or lifelong.

Anti-inflammatory Therapy:

• ·Corticosteroids remain the cornerstone of treatment. While their benefit is most pronounced in eosinophilic (allergic) disease, they can reduce the overall inflammatory burden even in neutrophilic bronchitis by suppressing cytokine-mediated inflammation and decreasing mucus production.
  • ·Prednisolone (oral): 1–2 mg/kg every 24 hours, tapered to the lowest effective dose over 4–8 weeks.
  • ·Inhaled fluticasone (via aerosol chamber/spacer): Preferred for long-term management to minimize systemic side effects (diabetes mellitus, obesity, adrenal suppression). Commonly dosed at 44–110 µg per actuation, 1–2 puffs twice daily.
• ·Doxycycline: Indicated if Mycoplasma felis is confirmed or strongly suspected on the basis of BAL cytology and clinical response; also has anti-inflammatory properties independent of its antibiotic activity. Typical dose: 5–10 mg/kg PO once daily for 4–6 weeks. Doxycycline should always be followed by water or food to prevent esophageal stricture in cats.

Bronchodilator Therapy: Bronchodilators are less central in non-allergic chronic bronchitis than in asthma because bronchospasm is not the primary mechanism, but they may provide symptomatic relief during exacerbations.

• ·Inhaled albuterol (salbutamol): 90 µg/actuation via metered-dose inhaler + spacer, as needed for acute episodes. Not for routine daily use due to risk of tachycardia and paradoxical bronchoconstriction with overuse.
• ·Theophylline (sustained-release): 25 mg/kg PO once daily at night. May improve mucociliary clearance and provide mild bronchodilation; requires careful dosing given the narrow therapeutic index in cats.

Mucolytic / Mucokinetic Agents:

• ·N-acetylcysteine (NAC): Administered via nebulization; reduces mucus viscosity and assists expectoration. Evidence in cats is largely anecdotal but widely used in clinical practice.
• ·Nebulization with saline: Humidification of airways helps loosen secretions; 0.9% NaCl nebulization for 10–15 minutes before coupage (chest physiotherapy) can facilitate mucus clearance.
• ·Coupage: Manual percussion of the thorax immediately after nebulization to mechanically dislodge airway secretions.

Environmental Management:

• ·Eliminate or minimize all identified inhaled irritants (cigarette smoke, dusty litter, aerosol sprays, scented candles).
• ·Use low-dust, unscented cat litter.
• ·Ensure adequate ventilation; consider HEPA air filtration.
• ·Keep the cat at a healthy body weight, as obesity independently worsens respiratory function.

Management of Exacerbations:

• ·Acute respiratory distress requires immediate oxygen supplementation (flow-by or oxygen cage at FiO₂ 40–60%).
• ·Rapid-acting bronchodilators (inhaled albuterol, or injectable terbutaline 0.01 mg/kg SC/IM) may be used.
• ·Short-course injectable or oral corticosteroids for rapid anti-inflammatory effect.
• ·Minimize patient stress; avoid excessive handling during acute episodes.

Treatment of Secondary Infections: When culture and sensitivity results confirm bacterial superinfection, targeted antibiotic therapy based on susceptibility data should be initiated. Common organisms include Pasteurella multocida and Pseudomonas spp. in bronchiectatic cats.

The prognosis for feline chronic bronchitis (non-allergic) is generally guarded to fair and is strongly influenced by the degree of structural airway damage present at the time of diagnosis. Unlike feline asthma, which may respond dramatically to anti-inflammatory therapy with near-complete resolution of symptoms, non-allergic chronic bronchitis is associated with irreversible remodeling changes that limit the achievable level of clinical improvement.

Key Prognostic Factors:

• ·Presence of bronchiectasis is the most important negative prognostic indicator; once bronchiectatic changes are established, they are permanent and predispose to recurrent secondary bacterial infections that are increasingly difficult to manage.
• ·Duration and severity of disease at diagnosis — cats diagnosed early with minimal remodeling have better outcomes than those with longstanding, severe changes.
• ·Response to initial therapy — cats showing meaningful improvement with corticosteroids within 4–8 weeks tend to do better long-term.
• ·Owner compliance with inhaled medication protocols (requiring a spacer/mask device) significantly affects outcomes.
• ·Control of secondary infections — each infectious exacerbation worsens airway architecture; early identification and treatment are critical.

Survival and Quality of Life: Specific peer-reviewed survival statistics for non-allergic feline chronic bronchitis as a distinct entity are limited in the current veterinary literature, as studies frequently combine this condition with feline asthma under the broader category of "feline lower airway disease." Many cats with mild-to-moderate disease achieve a reasonable quality of life with consistent medical management and environmental modification, living for years after diagnosis. Cats with advanced bronchiectasis and recurrent secondary pneumonia have a substantially worse prognosis and may require euthanasia due to progressive respiratory failure or declining quality of life. There is no curative therapy, and the goal of management remains control rather than resolution of disease.

Data on long-term mortality rates specific to non-allergic feline chronic bronchitis were not identified in the references cited above; a precise survival percentage cannot be responsibly stated, but overall disease-specific mortality from this condition alone (without concurrent severe bronchiectasis or secondary pneumonia) is considered relatively low with adequate management.

Complete prevention of feline chronic bronchitis (non-allergic) is not always possible, particularly in idiopathic cases. However, several evidence-based and clinically recommended measures can substantially reduce risk and slow progression:

Environmental Measures:

• ·Eliminate tobacco smoke exposure — this is the single most impactful modifiable risk factor; cats living with smokers have significantly increased exposure to airway irritants.
• ·Use low-dust, fragrance-free cat litter — conventional clay or dusty litter is a common and under-recognized airway irritant.
• ·Avoid aerosol sprays in the cat's environment, including air fresheners, cleaning sprays, perfumes, and insecticides.
• ·Install HEPA air purifiers in rooms where the cat spends most of its time.
• ·Ensure good household ventilation to reduce accumulation of volatile organic compounds and particulate matter.
• ·Avoid scented candles and incense, which release fine particulates and irritating compounds.

Infectious Disease Control:

• ·Maintain up-to-date core vaccinations, including feline herpesvirus-1 and calicivirus (components of the FVRCP vaccine), as these respiratory viruses can trigger or exacerbate lower airway inflammation.
• ·In multi-cat households or catteries, minimize crowding and ensure good air quality to reduce transmission of respiratory pathogens.
• ·Promptly investigate and treat acute respiratory infections to prevent progression to chronic disease.

Routine Veterinary Care:

• ·Regular wellness examinations allow early detection of subtle respiratory changes before significant remodeling occurs.
• ·Annual or biannual thoracic auscultation is recommended for middle-aged and older cats, particularly those with a history of respiratory disease.
• ·Maintain healthy body weight through appropriate diet and exercise; obesity is an independent risk factor for respiratory compromise.

There is no vaccine available specifically for feline chronic bronchitis (non-allergic). Prevention therefore relies primarily on environmental control and reduction of inciting factors.